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A peptide isolated from porcine gut according t ° its glucagon-like activity in liver (bioactive entero- 
glucagon) has been characterized immunologically, biologically and chemically: its potency relative to 
pancreatic glucagon in interacting with an antiglucagon antibody, hepatic glucagon-binding sites and 
hepatic adenylate cyclase was - 100%, 20% and 10%, respectively. In contrast, it is - 20-times more potent 
than glucagon in oxyntic glands, justifying the term 'oxyntomodulin'. Chemically, it consists in the 29 
amino acid-peptide glucagon elongated at its C-terminal end by the octapeptide Lys-Arg-Asn-Lys- 
Asn-Asn-Ile-Ala; accordingly, it is called 'glucagon-37'. 
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1. INTRODUCTION 
A peptide consisting of 37 amino-acid residues 
has been isolated [1] from porcine jejuno-ileum on 
the basis of its glucagon-like activity in liver (inter- 
action with hepatic glucagon-receptors and activa- 
tion of adenylate cyclase). Owing to its biological 
characteristics [2,3], this peptide is likely to repre- 
sent the hyperglycemic-glycogenolytic factor dis- 
covered in intestinal extracts [4]. Accordingly, the 
term °bioactive nteroglucagon' appears to be con- 
venient. However, the discovery of a tissue-specif- 
icity of this peptide at the level of oxyntic glands 
isolated from the rat stomach led us to propose the 
term 'oxyntomodulin' for it [5,6]. This report aims 
to describe the primary structure of this intestinal 
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peptide as well as its basic immunological nd bio- 
logical features. According to its chemical struc- 
ture, this peptide may be called 'glucagon-37'. 
2. MATERIALS AND METHODS 
2.1. Isolation procedure 
The peptide was isolated as in [1]. 
2.2. Amino acid analysis 
Amino acid analyses were carried out on a Beck- 
man 121M instrument after hydrolysis for 24 h at 
110°C with 6 N HC1 containing 0.5% phenol. 
2.3. Enzymatic digestions 
The peptides were hydrolyzed with two different 
enzymes: 
(1) Armillaria mellea protease (a gift from Dr P.L. 
Walton, ICI Laboratories, Cheshire) in 1% 
NI-I4HCO3 (pH 7.8) at an enzyme/substrate 
ratio of 1/100 (w/w) for 2 h at 37 ° C, conditions 
that resulted in a complete cleavage at the 
amino group of the lysine residue [7]; 
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(2) TLCK-treated a-chymotrypsin (EC 3.4.21.1) 
from Worthington (USA) in the same buffer 
for 7 min at 25°C with an enzyme/substrate 
ratio of 2/100 (w/w); these conditions were 
chosen because they allowed one to obtain 
cleavage of pancreatic glucagon at specific 
bounds (section 3). 
After the incubation time, the tubes containing 
the samples were placed in boiling water and kept 
boiling for 3 min. The digests were injected onto 
the HPLC column (see below) either directly after 
a 2-fold dilution with the chromatography solvent 
or after lyophilization and reconstitution i to the 
solvent. 
2.4. High performance liquid chromatography 
(HPLC) of the peptide J?agments 
After enzymic digestion, the peptidic fragments 
were separated by HPLC using a chromatographic 
apparatus in [1] fitted with a/z Bondapak C18 0.4 
x 30 cm column (Waters Assoc.). Aqueous olvent 
delivered by pump A consisted of 0.13% (w/w) 
CF3COOH (TFA) in water; organic solvent, deliv- 
ered by pump B, was CH3CN containing 0.05% 
CH3COOC2Hs. Peaks detected at 215 or 280 nm 
were integrated with a computing integrator 
(model 4100 Spectra Physics), collected into sil- 
anized glass tubes and lyophilized after evapora- 
tion in vacuo of the organic solvent. 
2.5. Determination of the amino-acid sequence of 
the fragments obtained 
We used the direct Edman degradation pro- 
cedure [8] as in [9]. The method was miniaturized 
to handle micro samples: Essentially, all volumes 
were reduced to l/5th and the glassware chosen 
accordingly. The PTH-amino acids obtained were 
identified by HPLC [10] with minor modifications. 
We also used for some residues the dansyl-Edman 
procedure [ 11]. 
2.6. Radioimmunoassay 
Glucagon-like immunoreactivity (GLI) was 
measured as in [3] using an antibody (666-6) pro- 
duced in our laboratory that recognizes imilarly 
glucagon-like immunoreactivity of either pancre- 
atic or intestinal origin. Specific (C-terminal) pan- 
creatic glucagon-like immunoreactivity was mea- 
sured with different antisera, K47 (a gift from Dr 
L. Heding, Novo Res. Inst., Copenhagen) and 30K 
(a gift from Dr R. Unger, University of Texas, 
Dallas). 
2.7. Radioreceptorassay in rat liver membranes 
This was performed with rat liver plasma mem- 
branes and 125I-pancreatic glucagon as in [3]. 
2.8. Study of adenylate cyclase activity in rat liver 
membranes 
The procedure used was described in [3]. 
2.9. Chemicals 
TFA was sequence grade from Pierce (USA) in 
l g ampules. CH3CN and CH3COOC2H5 were 
spectroscopic grade from Merck (Darmstadt). 
Chemicals used for sequence work were sequence 
grade, mostly from Pierce (USA). Peroxide-free 
ether [9] was from Mallinckrodt (USA). Other 
chemicals were pro analysi grade. 
3. RESULTS 
3.1. Immunological nd biological characterization 
On a molar basis, the intestinal peptide (referred 
to as G-37) possesses the same affinity as pancre- 
atic glucagon (referred to as G-29) for our anti- 
glucagon antibody (666-6) (fig.l). 
On the contrary, the affinity of G-37 for anti- 
bodies directed against he C-terminal portion of 
glucagon such as K47 or 30K, (usually referred to 
as 'specific' for pancreatic glucagon), was - 1% of 
that of G-29 (not shown). 
Fig.2 displays the interaction of pure G-37 with 
the glucagon (G-29)-receptors present in rat liver 
membranes, tt may be seen that the apparent po- 
tency of G-37 was - 20% of that of G-29 all along 
the dilution curves. 
Fig.3 shows that at all concentrations tested, G- 
37 was -10% as potent as G-29 in stimulating 
hepatic adenylate cyclase; the efficacy was identi- 
cal for G-37 and G-29. 
3.2. Structural studies 
Fig.4 displays the HPLC-separation of the pep- 
tidic fragments obtained from either pancreatic 
glucagon (upper panel) or the intestinal peptide 
(lower panel) after enzymic digestion with Armil- 
laria mellea protease. Two peptidic fragments were 
obtained from pancreatic glucagon: G-19, repre- 
senting the 1-t 1 fragment; and G-39, correspond- 
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Fig.l. Effect of glucagon (G-29) and the intestinal pep- 
tide (G-37) on the binding of 125I-glucagon to an anti- 
glucagon antibody produced in our laboratory (section 
2), the two peptides are compared on a molar basis. 
Conditions are indicated in section 2. 
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Fig.2. Effect of glucagon (G-29) and the intestinal pep- 
tide (G-37) on the binding of 125I-glucagon to rat liver 
plasma membranes [3]. The 2 peptides are compared on 
a molar basis. For details ee section 2. 
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ing to the 12-29 fragment. From the intestinal 
peptide, 4 peptidic fragments were obtained (EG- 
3, EG-10, EG-19, EG-39). It must be noticed that 
the relative peak heights and/or peak areas calcu- 
lated by the computing integrator between G-19 
and G-39 on the one hand and between EG-19 
and EG-39 on the other were not significantly dif- 
ferent, whatever the wavelength (215 or 280 nm) 
used (not shown). 
Fig.5 shows the separation of HPLC of the pep- 
tidic fragments obtained from either pancreatic 
glucagon (upper panel) or the intestinal peptide 
(lower panel) after enzymic digestion with a- 
chymotrypsin in conditions where specific bonds 
Fig.3. Effect of glucagon (G-29) and the intestinal pep- 
tide (G-37) on cyclic AMP accumulation i rat liver 
plasma membranes. Peptides are compared on a molar 
basis. Conditions are given in section 2. 
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Fig.4. HPLC-separation of the peptide fragments ob- 
tained after digestion with Armillaria mellea protease of 
glucagon (upper panel, G-peaks) and the intestinal pep- 
tide (lower panel, EG-peaks). Conditions for the diges- 
tion and for the HPLC-separation are in section 2. The 
data and absorbance ofthe peaks at 280 nm are given in 
table 1. 
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Fig.5. HPLC-separation of the peptidic fragments ob- 
tained after digestion with a-chymotrypsin under spe- 
cially designed conditions (sections 2 and 3) of glucagon 
(upper panel, G-peaks) and the intestinal peptide (lower 
panel, EG-peaks). Conditions for the digestion and for 
the HPLC-separation are given in section 2. The absor- 
bances of the peaks at 280 nm are given in table 1. 
are attacked. Indeed, no detectable splits were ob- 
served in our conditions at bonds 10-11 or 22-23, 
known to be more resistant han bonds 6-7,  13- 
14 and 25-26 [12]; in our conditions, the latter 
bonds were totally cleaved. Several points have to 
be stressed: 
(i) To 3 of the 4 fragments obtained from gluca- 
gon (G-15, G-17, G-30) corresponded 3 equiv- 
alent fragments from the intestinal peptide 
(EG-15, EG-17, EG-30); 
(ii) Similarly to the corresponding fragment from 
glucagon (G-15), EG-15 did not display any 
measurable absorbance at 280 nm, whereas, 
(iii) 
(iv) 
like G-17 and G-30, EG-17 and EG-30 did; 
The relative peak heights or peak areas calcu- 
lated between G-15, G-17 and G-30 were not 
significantly different from the relative values 
calculated between EG- 15, EG- 17 and EG-30, 
whatever the wavelength (215 or 280 nm); 
The single difference between the two runs 
(fig.5) was the presence in the digest of the in- 
testinal peptide of a fragment at 18 min (EG- 
18) that replaced the glucagon fragment G-13. 
Furthermore, EG-18 displayed relatively to 
the other peaks a higher absorbance at 215 nm 
than did G-13. 
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Table 1 
Data obtained from digestion, followed by separation of 
the peptidic fragments by HPLC, of glucagon (G-peaks) 
and the intestinal peptide (EG-peaks) 
Armillaria mellea digest a-Chymotrypsin digest 
Frag- HPLC A280 Frag- HPLC A280 
ment peak ment peak 
1-11 G-19 + 1-6 G-15 - 
1-11 EG-19 + 1-6 EG-15 - 
12-29 G-39 + 7-13 G-17 + 
12-29 EG-39 + 7-13 EG-17 + 
30-32 EG-3 - 14-25 G-30 + 
33-37 EG-10 - 14-25 EG-30 + 
26-29 G-13 - 
26-37 EG-18 - 
Digestion of the native peptides was performed by Ar- 
millaria mellea protease (left panel) or a-chymotrypsin 
(right panel). Conditions are described in section 2 
Table 1 summarizes the data obtained after en- 
zymic digestion of the peptides. 
Fig.6 displays the compared chemical structure 
of glucagon (glucagon-29) and the intestinal pep- 
tide (glucagon-37) according to all the data avail- 
able, including the amino acid sequence of  the 
fragments. 
Table 2 shows the amino acid composit ion of  
the intact peptide. If  we except the relatively low 
values obtained for Asx and Ser (91% and 85% of 
that expected, respectively), the data are in keep- 
ing with the sequence displayed in fig.6. 
GLUCAGON-29 
GLUCAGON-37 
/ _  
1 I 29 37 
HSQGTFTSDYSKYLDSRRAQDFVQWLMNT 
HSQGTFTSDYSKYLDSRRAQDFVQWLMNTKRNKNNIA 
t tt 
Fig.6. Comparison of the primary structure of glucagon 
(glucagon-29) and of the intestinal peptide (glucagon- 
37) according to the data available from the digestion 
with the 2 enzymes (fig.4,5) followed by amino acid se- 
quence determination of the fragments obtained. Thick 
arrows indicate the sites of action of Armillaria mellea 
protease; thin arrows indicate the sites of action of a- 
chymotrypsin used under the conditions in section 2. 
Amino acids are indicated by one-letter symbols [23]. 
Table 2 
Amino acid analysis of the intact G-37 molecule (as in 
section 2) 
Res. Calc. Nearest Theor. 
value integer value 
Cys 0 0 0 
Asx 6.41 6 7 
Thr 2.55 3 3 
Ser 3.41 3 4 
Glx 3.47 3 3 
Pro 0.31 0 0 
Gly 1.2 1 1 
Ala 2.16 2 2 
Val 0.92 1 1 
Met 0.97 1 1 
Ile 0.99 1 1 
Leu 2.18 2 2 
Tyr 2.02 2 2 
Phe 1.69 2 2 
Trp - - 1 
Lys 3.2 3 3 
His 1.11 1 1 
Arg 3.46 3 3 
The relatively low values obtained with Ser and Asx 
may be attributed to some degradation of the sensitive 
serine residue and to a slight problem in integration of 
the Asx peak, respectively. The tryptophan residue can- 
not be identified using the present methods (destroyed 
by acid hydrolysis) 
4. D ISCUSSION 
On a molar basis, the newly isolated intestinal 
peptide possessed for our anti-glucagon antibody, 
which is representative of the so called 'non-specif-  
ic anti-glucagon antibodies', an affinity which was 
similar to that of pancreatic glucagon. On the con- 
trary, its affinity for the anti-glucagon antibodies 
directed against the C-terminal portion of the 
glucagon molecules was - 1% of that of pancreatic 
glucagon. These data are in keeping with the struc- 
ture of the molecule (fig.6); indeed, the C-terminal 
extension is likely to hinder the interaction be- 
tween the molecule and the antibodies directed 
against he C-terminal portion of glucagon. 
On the same molar basis, the calculated affinity 
of the intestinal peptide for the hepatic glucagon- 
receptor was 4-5- t imes lower than that of  pan- 
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creatic glucagon, whereas the former was about 
one order of magnitude less potent than the latter 
in stimulating hepatic adenylate cyclase. This poor 
(-2-fold) difference between the 2 relative poten- 
cies rules out the possibility pointed out in [13,14] 
that the intestinal glucagon-like peptide that dis- 
plays an affinity for the hepatic glucagon-recep- 
tots, thus inhibiting the glycogenolytic effect of 
pancreatic glucagon and leading to hypoglycemia. 
On the contrary, bioactive enteroglucagon is a 
good agonist of glucagon at the hepatic level and a 
possibility exists that in some physiological and/or 
pathological states, where high levels of the intesti- 
nal peptide together with low levels of pancreatic 
glucagon are present in the portal vein, the former 
peptide may be of some importance in regulating 
blood glucose through glycogenolysis/gluconeo- 
genesis. In any case, the action of the pure intesti- 
nal peptide on the hepatic glucagon-sensitive sys- 
tems and the fact that this peptide is the main, if 
not the single, intestinal peptide that possesses 
these characteristics [1] strongly supports the idea 
that the 37 amino acid glucagon-like peptide from 
intestine is the hyperglycemic-glycogenolytic pep- 
tide discovered in [4]. Accordingly, the term 'bio- 
active enteroglucagon' appears to be convenient. 
The demonstration [5] that bioactive entero- 
glucagon possesses, in addition to its glucagon-like 
effect in liver, a tissue-specific action at the level of 
gastric glands isolated from the fundic part of the 
rat stomach, suggests that the main physiological 
role of the intestinal peptide is not at the hepatic 
level but at the level of the acid-secreting astric 
area that contains the oxyntic glands. Accordingly, 
we have proposed the term 'oxyntomodulin' for 
this peptide [5,6]. This tissue-specificity is further 
supported by the demonstration [15] that oxyn- 
tomodulin is much more potent than pancreatic 
glucagon in inhibiting pentagastrin-induced gastric 
acid secretion in rat in vivo; the relative potency of 
the intestinal peptide vs that of the pancreatic pep- 
tide is similar (15-20 times in favor of the former) 
both in the in vitro [5] and the in vivo [15] models. 
If we compare the potency of the intestinal peptide 
to that of glucagon in the 2 rat tissues, it appears 
that oxyntomodulin is -200-times more potent 
relative to glucagon in stomach than in liver. This 
large difference between the 2 peptides in their 
tissue-specificity ogether with the fact that the in- 
testinal glucagon-like peptides are probably re- 
leased into blood under physiological conditions 
that are quite different to those under which pan- 
creatic glucagon is released (review [16]) strongly 
suggest that the 2 peptides are different physiologi- 
cal entities; according to its high potency in inhib- 
iting gastric acid secretion[15], it is reasonable to 
suggest an enterogastrone role for oxyntomodulin. 
As far as the chemical structure of the intestinal 
peptide is concerned, we have suggested [6] that 
the peptide contains the whole (1-29) glucagon 
molecule elongated at its C-terminal end by a 
basic octapeptide (Lys -Arg -Asn-Lys -Asn-  
Asn-l le-Ala). The doubt concerning a possible 
modification in the N-terminal portion of the 
glucagon moiety [6] may be ruled out according to 
these data. Indeed, we can confirm that, in [6], a 
modification (e.g., a deamidation of the glutamine 
residue in position 3) had occurred during the stor- 
age of the peptide used. Thus the single structural 
difference between G-29 and G-37 is the presence 
in G-37 of the basic octapeptide. The presence of 
this extension explains not only the hindrance ob- 
served of the interaction with some antibodies (see 
above) but also with hepatic glucagon-sensitive 
systems. However, it is noteworthy that despite the 
8 amino acid extension, the decrease in affinity for 
the glucagon-receptors is not striking; this con- 
trasts with the dramatic loss of affinity of the C- 
terminally modified glucagon molecules [17]. 
In sharp contrast o what is observed in liver, G- 
37 is -20-times more potent than glucagon in 
stomach both in vitro [5] and in vivo [15]; it is thus 
very likely that the oxyntic glands contain a recep- 
tor which recognizes with a much higher affinity 
the 37 amino-acid peptide than the 29 amino-acid 
peptide; the basic octapeptide is thus most proba- 
bly deeply involved in the interaction with the gas- 
tric receptor. 
Two peptides that contain glucagon 1-29 plus a 
C-terminal extension in the form of a basic oc- 
tapeptide have been isolated: one was the 37 
amino-acid peptide 'proglucagon fragment' [18] of 
pancreatic origin; the other was the 69 amino-acid 
'glicentin' or 'proglucagon' [19] that contains an 
additional 32 amino-acid N-terminal extension. A 
structural difference appears in the published se- 
quences: residues 4 and 5 of the C-terminal exten- 
sion were Asn-Lys in the 'proglucagon fragment' 
when the order was Lys--Asn in 'glicentin'. As re- 
ported [6], we found in the 37 amino-acid intesti- 
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Fig.7. Schematic processing of proglucagon supposed to 
occur in pancreas [19] and in intestine (according to 
these results). For details, see section 4. 
nal peptide the same order Lys--Asn as in the 'glic- 
entin' sequence. Some technical artefact [6,19] 
is likely to explain the sequence in [18]. This is fur- 
ther supported by the observation (unpublished) 
that the pancreas contains, in addition to G-29, 
small amounts of a peptide resembling in all ways 
the intestinal G-37. 
According to the fact that both the N-terminal 
and the C-terminal extensions of glucagon-29 be- 
gin with a basic dipeptide, as in most of the pro- 
hormones, glucagon-29 may be released from pro- 
glucagon by enzymatic cleavage of the basic di- 
peptide at both the N-terminal and the C-terminal 
extensions [ 19]. 
According to our data, we can speculate (fig.7) 
that: 
(2) In contrast, (lower panel) the processing en- 
zyme that cleaves proglucagon at the amino 
end (Lys-Arg dipeptide) of the glucagon mole- 
cule appears to be present also in intestine, but 
the processing enzyme that cleaves at position 
29 of glucagon (Lys-Arg dipeptide) is proba- 
bly lacking or inactive in intestine*; according- 
ly, the 37 amino-acid peptide 'oxyntomodulin' 
is released and, owing to its tissue specificity, 
acts on its target tissues, particularly stomach. 
It remains, however, to be established what are 
the exact physiological conditions under which 
this peptide is released and the regulatory 
mechanisms involved. 
Owing to the largely confusing terminology for 
describing the peptides of the glucagon-family, we 
propose for the 3 known peptides the chemical 
structure-related terms glucagon-29 for pancreatic 
glucagon, glucagon-37 for the peptide that we have 
isolated from porcine intestine as well as that iso- 
lated from pancreas [18] (these 2 peptides being 
most probably identical) and glucagon-69 for the 
so-called 'glicentin' or 'proglucagon'. This termi- 
nology is related to the fact that all these peptides 
contain the whole glucagon molecule and de- 
scribes the number of amino-acid residues, what- 
ever the type of extension (N- and/or C-terminal). 
Such a terminology is now commonly used for the 
N-terminally extended molecules, e.g., the somato- 
statin family: somatostatin-14, somatostatin-28 
[20,21]. On the other hand, a universal denomina- 
tion of the peptides structurally related to a pre- 
viously named one will await an internal con- 
sensus. 
In conclusion, the isolation of this glucagon-re- 
lated intestinal peptide [1], the determination of its 
chemical structure (this paper) and the discovery 
of its tissue-specificity [5,15] is expected to shed 
new light on the biological significance of the pep- 
tides of the glucagon-family. 
(1) The mechanism above [19} is operative at the 
pancreatic level (upper panel) leading to the re- 
lease into the blood stream of the G-29 mole- 
cule that will act on its target tissues, par- 
ticularly liver. 
* These differences between pancreas and intestine are 
not absolute since small amounts of G-37 are present in 
rat pancreas (unpublished) as well as small amounts of 
G-29 in intestine of rat (unpublished) and human [22] 
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